Hengrui Medicine gets green light for clinical trials
Jiangsu Hengrui Medicine (SSE:600276) announced that its subsidiaries, Suzhou Shengdiya Biomedical and Shanghai Shengdi Pharmaceutical, have been granted clinical trial approval for SHR-A2009 injection and adebrelimab injection by the National Medical Products Administration. The trials will assess the safety, tolerability, and efficacy of SHR-A2009 in combination with anti-tumor therapies for patients with advanced solid tumors. SHR-A2009, an anti-HER3 antibody-drug conjugate, has seen cumulative R&D investment of approximately RMB 114.6 million. Adebrelimab injection, a PD-L1 monoclonal antibody, has had cumulative R&D investment of approximately RMB 784.71 million. The company cautioned that the drug still needs to undergo clinical trials and regulatory review before it can be commercialized.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime